Listen to hosts Samantha Spiers and Wildcard Cameron discuss the FDA's approval of Aduhelm, a new drug developed to treat those with Alzheimer's disease. Discussion includes what is this drug, why is its approval controversial, and why did the FDA go ahead and approve it.

Post production by Scott Stronach.   

Check out other Sample Size episodes here and reach out to us on twitter or email us at samplesizeshow.gmail.com if you have any topics you want us to cover in the future!

Please consider donating to organizations providing supplies and relief to India to help with the COVID-19 pandemic. Visit UNICEF or Mutual Aid India.  

Sources: 

https://www.npr.org/2021/06/07/1003964235/fda-approves-controversial-alzheimers-drug-aducanumab 

https://www.npr.org/2021/06/11/1005567149/3-experts-have-resigned-from-an-fda-committee-over-alzheimers-drug-approval 

https://www.nia.nih.gov/health/what-alzheimers-disease 

https://www.forbes.com/sites/joewalsh/2021/06/17/manchin-wants-biden-to-oust-fda-chief-over-controversial-alzheimers-drug-approval/?sh=43bb08626c80 

https://www.washingtonpost.com/health/2021/06/17/alzheimers-drug-controversy/ 

https://pubmed.ncbi.nlm.nih.gov/33656288/ 

https://www.fda.gov/advisory-committees 

Support this show http://supporter.acast.com/sample-size.

Hosted on Acast. See acast.com/privacy for more information.